Article

jdsupra.com on 2021-12-09 20:24

FDA Issues Draft Guidance for Sponsors and Other Stakeholders on Using Registries as RWD to Support Regulatory Decision-Making

The U.S. Food and Drug Administration (FDA) issued its third draft guidance under the Real-World Evidence (RWE) Program on November 29, 2021. In ...

Related news

FDA Releases Draft Guidance for Sponsors on How to Comply with Study Data Standards When Submitting RWD-Sourced Study Data jdsupra.com
FDA invites comment on guidance on meetings with OTC sponsors jdsupra.com
It’s Starting to Register: FDA Draft Guidance Addresses Use of Registries to Support Regulatory Decision-Making for Drugs & Biological Products jdsupra.com
Cures
FDA RWD/RWE regulatory considerations in draft guidance highlight opportunities and challenges - Laying groundwork for high-quality evidence to support regulatory decisions jdsupra.com
Cures
FDA MIE pilot hints at expanding regulatory paradigm for bioequivalence jdsupra.com
CMonogram Provides Regulatory Update Following Meeting with FDA charlotteobserver.com
FDA Regulatory Framework for Cosmetics Gets Major Overhaul jdsupra.com
Cong
FDA Proposes Restructuring of Its Regulatory Oversight of Human Food jdsupra.com
Deputy Commissioner
FDA Releases Draft Guidance on Remote Regulatory Assessments jdsupra.com
EPA, USDA, and FDA to Clarify Overlapping Biotechnology Regulatory Frameworks jdsupra.com
Soca
New FDA pilot offers expedited drug program sponsors expanded FDA meeting opportunities on manufacturing issues jdsupra.com
Phase 2 , Fast Track
Former FDA Commissioners, Industry Groups Show Support for Modernized FDA Regulatory Framework jdsupra.com
FDA launches temporary “TRIP” program to help HCT/P sponsors gain regulatory clarity jdsupra.com
California , United States , Switzerland
New CCUS Regulatory Handbook a Practical Guide for Stakeholders, Practitioners and Policymakers jdsupra.com
United States
FDA Laboratory Developed Test Oversight: What Stakeholders Need to Know About Proposed Overhaul jdsupra.com
FDA proposes annual summary reporting requirements for Right to Try drug sponsors, manufacturers jdsupra.com
FDA Issues Final Guidance on Informed Consent for IRBs, Clinical Investigators, and Sponsors jdsupra.com
LDTs: FDA Rolls Out a Phased Implementation for New Regulatory Requirements jdsupra.com
Infectious Diseases , Unmet , United States
U.S. FDA: labeling guidance for sponsors incorporating prescription drug use-related software jdsupra.com
FDA Draft Guidance Instructs Sponsors on Content and Timing of Diversity Plans for Clinical Trials jdsupra.com